NEA Management Company, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), NEA Management Company, LLC reported 41 stock positions worth $1.8 billion. Its top holding was Arcellx (ACLX) at 16.2% of the portfolio, followed by Verona Pharma (VRNA, 14.6%) and Tempus AI Class A (TEM, 10.3%). Compared with Q3 2024, it opened 1 new position, sold out of 2, added to 2 and reduced 1. The biggest buy was a new position in Onkure Therapeutics Class A (OKUR) and the biggest sale an exit from Reneo Pharmaceuticals.
- Most Recent 13F
- Q2 2026
- Location
- TIMONIUM, MD
- CIK
- 0001512848
- Portfolio Value
- $1.8B (Q4 2024)
- SEC Filing
- 0000897069-25-000248 ↗ filed Feb 14, 2025
Holdings Value
Holdings 41 stocks · $1.8B
| ACLX Arcellx Inc. | 16.21% | 3,745,262 | $287.2M | No change |
| VRNA Verona Pharma Ltd. | 14.64% | 5,584,753 | $259.4M | No change |
| TEM Tempus AI Inc. Class A | 10.26% | 5,385,979 | $181.8M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 9.19% | 2,909,956 | $162.9M | No change |
| NN Nextnav Inc. | 7.19% | 8,189,156 | $127.4M | No change |
| COUR Coursera Inc. | 6.17% | 12,867,769 | $109.4M | No change |
| SVRA Savara Inc. | 4.24% | 24,471,264 | $75.1M | No change |
| MBX MBX Biosciences Inc. | 3.76% | 3,614,486 | $66.6M | No change |
| CRSP Crispr Therapeutics AG | 3.53% | 1,587,854 | $62.5M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 3.01% | 7,692,298 | $53.4M | No change |
| TRVI Trevi Therapeutics Inc. | 2.76% | 11,370,376 | $48.8M | No change |
| KRRO Korro Bio Inc. | 2.34% | 1,090,793 | $41.5M | No change |
| AUPH Aurinia Pharmaceuticals Inc. | 2.01% | 3,969,834 | $35.6M | No change |
| CVRX CVRX Inc. | 1.45% | 2,026,083 | $25.7M | Reduce -14.5% |
| ZBIO Zenas Biopharma Inc. | 1.21% | 2,613,948 | $21.4M | No change |
| NEUE Neuehealth Inc. | 1.14% | 2,726,917 | $20.2M | No change |
| GOSS Gossamer Bio Inc. | 0.92% | 18,093,034 | $16.4M | No change |
| CELC Celcuity Inc. | 0.92% | 1,250,001 | $16.4M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 0.90% | 1,960,169 | $15.9M | No change |
| CSBR Champions Oncology Inc. | 0.83% | 1,713,720 | $14.7M | No change |
| ORIC Oric Pharmaceuticals Inc. | 0.71% | 1,566,081 | $12.6M | Add +4.4% |
| XFOR X4 Pharmaceuticals Inc. | 0.62% | 14,986,793 | $11.0M | No change |
| BZFD Buzzfeed Inc. | 0.58% | 3,833,473 | $10.2M | No change |
| RGLS Regulus Therapeutics Inc. | 0.58% | 6,467,802 | $10.2M | No change |
| GERN Geron Corp. | 0.55% | 2,776,409 | $9.8M | No change |
| BDTX Black Diamond Therapeutics I | 0.54% | 4,448,757 | $9.5M | No change |
| ADAPY Adaptimmune Therapeutics-ADR | 0.52% | 17,079,778 | $9.2M | No change |
| SGMT Sagimet Biosciences Inc. Class A | 0.51% | 2,000,275 | $9.0M | No change |
| NKTX Nkarta Inc. | 0.50% | 3,568,781 | $8.9M | No change |
| ALLK Allakos LLC | 0.42% | 6,147,260 | $7.4M | No change |
| INZY Inozyme Pharma Inc. | 0.38% | 2,437,689 | $6.8M | No change |
| MRKR Marker Therapeutics Inc. | 0.29% | 1,625,678 | $5.1M | Add +51.7% |
| OKUR Onkure Therapeutics Inc. Class A | 0.23% | 478,548 | $4.1M | New |
| SYBX Synlogic Inc. | 0.23% | 2,922,772 | $4.1M | No change |
| DM Desktop Metal Inc. Class A | 0.19% | 1,439,892 | $3.4M | No change |
| IVA Inventiva SA - ADR | 0.18% | 1,462,586 | $3.1M | No change |
| LXRX Lexicon Pharmaceuticals Inc. | 0.10% | 2,382,286 | $1.8M | No change |
| SNTI Senti Biosciences Inc. | 0.09% | 442,615 | $1.6M | No change |
| IKENA ONCOLOGY INC | 0.06% | 600,063 | $984K | No change |
| AFMDQ Affimed NV | 0.03% | 442,648 | $527K | No change |
| UP Wheels Up Experience Inc. | 0.01% | 106,125 | $175K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| RENEO PHARMACEUTICALS INC | Sold out | 0.00% | −0.44 |
| MYND Mynd.ai Inc. | Sold out | 0.00% | −0.01 |
| CVRX CVRX Inc. | Reduce -14.5% | 1.45% | +0.31 |
Portfolio Buys Q3 2024 → Q4 2024
Notes & Other Activity Q3 2024 → Q4 2024
| TUYA Tuya Inc. | SPONSERED ADS | New | 0 | $0 |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.6B | TRVI, MBX, GLUE, CELC, SGP |
| Q1 2026 | 26 | $1.8B | ACLX, CELC, SGP, TRVI, SVRA |
| Q4 2025 | 27 | $2.0B | CELC, RYTM, ACLX, TRVI, SVRA |
| Q3 2025 | 29 | $1.8B | RYTM, ACLX, VRNA, COUR, TRVI |
| Q2 2025 | 32 | $1.3B | ACLX, VRNA, RYTM, COUR, CRSP |
| Q1 2025 | 37 | $1.3B | ACLX, VRNA, RYTM, TEM, COUR |
| Q4 2024 | 41 | $1.8B | ACLX, VRNA, TEM, RYTM, NN |
| Q3 2024 | 42 | $1.8B | ACLX, TEM, VRNA, RYTM, SVRA |
| Q2 2024 | 41 | $1.3B | ACLX, TEM, RYTM, SVRA, COUR |
| Q1 2024 | 44 | $1.6B | ACLX, CRSP, RYTM, SVRA, COUR |